| For: | Li QY, Gong T, Huang YK, Kang L, Warner CA, Xie H, Chen LM, Duan XQ. Role of noncoding RNAs in liver fibrosis. World J Gastroenterol 2023; 29(9): 1446-1459 [PMID: 36998425 DOI: 10.3748/wjg.v29.i9.1446] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v29/i9/1446.htm |
| Number | Citing Articles |
| 1 |
Kurt Sartorius, Yanglong Wang, Benn Sartorius, Samuel O. Antwi, Xiaodong Li, Anil Chuturgoon, Chongyuan Yu, Yunjie Lu, Yu Wang. The interactive role of microRNA and other non-coding RNA in hepatitis B (HBV) associated fibrogenesis. Functional & Integrative Genomics 2025; 25(1) doi: 10.1007/s10142-024-01519-4
|
| 2 |
Taicheng Zhang, Jie Jing, Yaodan Liang, Jianming Luo, Dongyu Cheng, Shanyu Qin, Haixing Jiang. Resveratrol-stimulated macrophage exosomes delivering lncRNA Snhg6 inhibit liver fibrosis by modulating the NF-κB pathway. Genomics 2025; 117(3) doi: 10.1016/j.ygeno.2025.111043
|
| 3 |
László Orosz, Károly Péter Sárvári, Áron Dernovics, András Rosztóczy, Klára Megyeri. Pathogenesis and clinical features of severe hepatitis E virus infection. World Journal of Virology 2024; 13(2): 91580 doi: 10.5501/wjv.v13.i2.91580
|
| 4 |
Jing Dai, Guo-Hui Zhong, Jun-Xing Yang, Xiao-Yu Tan, Dong Dai, Ming-Yi Li. Long noncoding RNA X-inactive-specific transcript promotes hepatic fibrosis by suppressing ferroptosis in hepatic stellate cells via the miR-663a/GPX4 axis. Frontiers in Physiology 2026; 16 doi: 10.3389/fphys.2025.1734886
|
| 5 |
Margherita Sisto, Sabrina Lisi. Targeting Interleukin-17 as a Novel Treatment Option for Fibrotic Diseases. Journal of Clinical Medicine 2023; 13(1) doi: 10.3390/jcm13010164
|
| 6 |
Hai-Quan Wang, Lu Zhang, Ming-Jie Li, Rong-Quan He, Di-Yuan Qin, Bin Li, Jian-Di Li, Ke-Jun Wu, Shi-De Li, Han He, Zhen-Bo Feng, Gang Chen. Tumor microenvironment: new era in exosomal circRNA research - a bibliometric analysis. Extracellular Vesicles and Circulating Nucleic Acids 2025; 6(2) doi: 10.20517/evcna.2024.102
|
| 7 |
Kexin Yu, Yuanxiang Jin, Yidong Zhou, Qiaoping Xu. Long non-coding RNA in hepatocellular carcinoma: mechanistic insights and therapeutic perspectives. Cellular Oncology 2025; 48(6) doi: 10.1007/s13402-025-01119-9
|
| 8 |
Maryam Jadid Tavaf, Mahboobeh Ebrahimi Varkiani, Saeid Abroun, Pedram Asadi‐Sarabi, Shukoofeh Torabi, Elham Rismani, Mohammad Majd Hammour, Andreas K. Nüssler, Massoud Vosough. Epigenetic Regulation of Liver Fibrosis: Mechanisms and Therapeutic Implications. Portal Hypertension & Cirrhosis 2026; doi: 10.1002/poh2.70064
|
| 9 |
Hui Ling, Xian-Chen Wang, Zhi-Yan Liu, Sui Mao, Jing-Jing Yang, Ji-Ming Sha, Hui Tao. Noncoding RNA network crosstalk in organ fibrosis. Cellular Signalling 2024; 124 doi: 10.1016/j.cellsig.2024.111430
|
| 10 |
Youtian Zhang, Long Ren, Yinting Tian, Xiaohu Guo, Fengxian Wei, Yawu Zhang. Signaling pathways that activate hepatic stellate cells during liver fibrosis. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1454980
|
| 11 |
Yan Zhao, Xin-quan Wu, Shu-li Liao. Rutaecarpine alleviates liver fibrosis by modulating the TRPV1/Connexin 43 axis: A study based on transcriptome data, single-cell sequencing data, and cell experiments. Biochemical and Biophysical Research Communications 2025; 781 doi: 10.1016/j.bbrc.2025.152506
|
| 12 |
杰 董. Serum Markers for Liver Fibrosis Assessment in Patients with Chronic Hepatitis B. Advances in Clinical Medicine 2023; 13(10) doi: 10.12677/ACM.2023.13102362
|
| 13 |
Sana Raza, Rukshana Mahamood, Pratik Medhe, Ambuj Shahi, Abhishek Yadav, Archana Tewari, Rohit A. Sinha. Sterile inflammation in MASH: emerging role of extracellular RNA and therapeutic strategies. npj Metabolic Health and Disease 2025; 3(1) doi: 10.1038/s44324-025-00083-0
|
| 14 |
Auriane de Pellegars-Malhortie, Laurence Picque Lasorsa, Thibault Mazard, Fabien Granier, Corinne Prévostel. Why Is Wnt/β-Catenin Not Yet Targeted in Routine Cancer Care?. Pharmaceuticals 2024; 17(7) doi: 10.3390/ph17070949
|
| 15 |
Sara Mohammadi Miyanroodan, Muhammad Sohail. Recent advances in engineered exosomes for targeted microRNA delivery to reverse liver fibrosis. Journal of Drug Delivery Science and Technology 2026; 122 doi: 10.1016/j.jddst.2026.108447
|
| 16 |
Qiumei Zhou, Xue Zhang, Sen Chen, Chang Fan, Kaiqiang Wan, Chao Wu, Xiaoli Wang, Wancun Zhang, Hui Jiang. Shugan Jianpi Formula attenuate liver fibrosis via regulation of miR-193a-3p/TGF-β2 in hepatic stellate cells: An in vivo and in vitro study. Journal of Ethnopharmacology 2025; 340 doi: 10.1016/j.jep.2024.119120
|
| 17 |
A.E. Abaturov, A.O. Nikulina. Epigenetic antifibrotic effect of expression of long noncoding RNAs lncR-p21, MEG3, H19 on the development of fibrosis in metabolic dysfunction-associated steatotic liver disease (systematic review and meta-analysis). GASTROENTEROLOGY 2026; 60(2) doi: 10.22141/2308-2097.60.2.2026.727
|
| 18 |
Lin Yang, Jie Wang, Chunhong Wang, Yuqi Xu, Yuelin Fang, Dian Cai, Mingxuan Yu, Xinxin Zhang. Hepatic stellate cells targeting lipid nanoparticle mediated RNA delivery for liver fibrosis treatment by autophagy regulation. Acta Pharmaceutica Sinica B 2026; doi: 10.1016/j.apsb.2026.08.010
|
| 19 |
Zhang Chu-Ning, Shan Guan-Yue, Wan Hui, Zhang Yu-Xin, Gao Zhi-Cheng, Li Hai-Jun. Hepatic Stellate Cells Interact with the Immune System: A Bidirectional Crosstalk Network Driving Liver Fibrosis. Fibrosis 2026; 4(2) doi: 10.70322/fibrosis.2026.10006
|